OA 中文
Olymvax Biopharmaceuticals Inc. and Griffith University Jointly Initiated the Development of Coronavirus Disease (COVID-19) Vaccine

On February 24, 2020, Olymvax Biopharmaceuticals Inc. and Griffith University signed a memorandum of understanding, both parties agreed to cooperate on the coronavirus disease (COVID-19) vaccine.


Olymvax R & D team will cooperate with Professor Michael Good of the Griffith University Institute for Glycomics in the Joint Laboratory for Vaccine Development to develop the COVID-19 vaccine. Griffith University will be responsible for screening of vaccine antigens and some animal experiments, while Olymvax will complete pre-clinical validation and production of clinical samples. The two parties agreed that the research and development the peptide vaccine will start with the spatial structure of coronavirus S protein to build a large antigen library and to screen out the vaccine antigens that have the best immunogenicity.


Griffith University in Australia was founded in 1971. It has an international reputation for the first-class performance in education and research, and is recognized as one of the most innovative and influential universities in the Asia-Pacific region. The Institute of Glycomics at Griffith University was established in 2000 by Professor Mark Von Itzstein, who was responsible for designing and synthesizing Relenza, the first anti-flu drug. There are more than 200 scientists in the institute, equipped with advanced biosafety level 3 laboratory (PC3 / BSL-3) and rich experience for international cooperated vaccine development.


On 23rd, the official media released the content of the Deployment Conference on Impelling the Control on COVID Epidemic and Economic Development, emphasizing that: "we should expand international and regional cooperation, keep good communication with WHO, share epidemic prevention experience with relevant countries, and strengthen international cooperation in the development of antiviral drugs and vaccines." There are multiple technical challenges in the way of a vaccine development, numerous cooperations are needed. Olymvax will continue to integrate global resources, maintain cooperation with all parties, striving to achieve technological breakthroughs for the development of coronavirus vaccine.